Phase I/II Study With Temsirolimus Versus no add-on in Patients With Castration Resistant Prostate Cancer (CRPC) Receiving First-line Docetaxel Chemotherapy.
Phase of Trial: Phase I/II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Temsirolimus (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CEPTAS
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Feb 2015 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.